Received Mar 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
Raynaud's phenomenon; This non-serious case was reported by a consumer and described the occurrence of raynaud's phenomenon in a 63-year-old female patient who received DTPa (Reduced antigen) (Tdap Vaccine) for prophylaxis. Additional patient notes included no Prior history of this condition. no prior vaccines. patient do not even take aspirin. On an unknown date, the patient received Tdap Vaccine. On an unknown date, an unknown time after receiving Tdap Vaccine, the patient experienced raynaud's phenomenon (Verbatim: Raynaud's phenomenon). The outcome of the raynaud's phenomenon was not resolved. It was unknown if the reporter considered the raynaud's phenomenon to be related to Tdap Vaccine. It was unknown if the company considered the raynaud's phenomenon to be related to Tdap Vaccine. Additional Information: GSK Receipt Date: 22-FEB-2026 The batch number was not provided upon follow up with the reporter.
Comments: no Prior history of this condition. no prior vaccines. patient do not even take aspirin